High value deal with Bamboo Therapeutics starts to come to fruition with start of small study in Duchenne muscular dystrophy, which aims at underlying cause as opposed to symptoms of disease.
Pfizer Inc.is stressing its commitment to the development of gene therapy for rare diseases by moving a Duchenne muscular dystrophy candidate into the clinic, after distancing itself from development of the portfolio it had built around allogeneic chimeric receptor T-cell (CAR-T) cellular therapies.
Pfizer recently announced the transfer of CAR-T assets gained in 2014 and 2015 from Cellectis SA and Servier...
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.
In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.
The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
